Regeneron Pharmaceuticals IncREGN
▲ ポジティブ需要関連度
Dupixent sales surged 30.8% to €4.17B, co-developed with Regeneron, driving revenue and growth expectations.
銘柄への影響 4
Biotech & Genomic Medicine
Regeneron Pharmaceuticals Inc
AbbVie IncABBV
▼ ネガティブ競争関連度
Dupixent's strong sales and market leadership in inflammatory diseases pose competitive pressure on AbbVie's Humira and Skyrizi.
Pfizer IncPFE
▼ ネガティブ競争関連度
Dupixent's dominance in inflammatory diseases, including COPD expansion, competes with Pfizer's Xeljanz and other pipeline assets.
Health Care
Sanofi SASAN
▲ ポジティブ需要関連度
Dupixent sales surged 30.8% to €4.17B, with strong growth outlook and market leadership.